Exogenus Therapeutics is an early-stage research and development company developing healthcare solutions based on Extracellular Vesicles (EVs) and Exosomes. Founded in 2015,
Exogenus is a pioneer in the field of EVs/Exosome-based therapeutics, and a recognized innovator in Umbilical Cord Blood clinical use. Leveraging on its experience and recognition in this space, Exogenus mission is to foster a new era of EVs/Exosomes-based solutions to solve major healthcare challenges, based on the development of its own products, and providing guidance to other partners developing this type technologies for clinical use.
Exogenus Therapeutics announces collaboration with Boehringer Ingelheim to explore the use of extracellular vesicles in regenerative medicine applications
Exogenus Therapeutics is one of the five companies presenting projects in the Innocore Challenge. The initiative is part of the project “InnoCore – Core Technologies for Education and...
Exogenus Therapeutics CEO, Joana Simões Correia, is again an invited speaker at the 3rd Exosome Based Therapeutic Development Summit, taking place virtually on November 17th and 18th, as...